PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.
Treatment of the HER2 expressing cells with the PROTAC ERα Degrader-1 (without Ab; compound P1) results in a decreased estrogen receptor-alpha (ERα) levels[1].
[1]. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
















